Dr. Edward F. McClay, MD

Dr. McClay practices at Rashedi DMD PC in San Marcos, California.

Dr. McClay's NPI, 1497727465, was assigned on February 3, 2006. Dr. McClay graduated from Lewis Katz School of Medicine in 1980. Dr. McClay holds California license G64594.

Dr. McClay's primary practice is Rashedi DMD PC, at 838 Nordahl Rd, San Marcos, CA 92069 in San Diego County. The practice phone is (760) 294-7041.

Dr. McClay's primary practice is Rashedi DMD PC in San Marcos, California. The medical group on file is California Cancer Associates for Research and Excellence (cCARE). Dmand AI also links Dr. McClay to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McClay practices. Vendor and product names are available with a free account.

Medical oncology is Dr. McClay's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. McClay is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. McClay's licenses on file in 3 states: California, South Carolina and Pennsylvania.

Dmand AI lists acid reflux, chronic anemia, chronic diabetes, chronic hypertension, chronic kidney disease, enlarged prostate, enlarged thyroid and hearing loss and impairment among the conditions Dr. McClay treats.

CMS data shows 93,611 Medicare services from Dr. McClay across 43 procedure codes in 2024, for 567 Medicare patients. Medicare paid $2,512,520 for them.

CMS counts 567 Medicare patients who saw Dr. McClay in 2024. The largest group is 75 to 84, with 240 patients. 75% of them have high blood pressure, and 74% have high cholesterol. 19% are also on Medicaid. Their average risk score is 2.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. McClay's median patient age at 72, with 64% women.

In 2024, Dr. McClay wrote 547 Medicare Part D claims for 135 patients. 69% of them were for generic drugs. CMS names the drug for 282 of them, across 17 drugs with 11 or more claims each, at $550,308 in total drug cost. In 2023, CMS named 308 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. McClay for performance year 2024, reported as part of a group. Dr. McClay accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 69 papers to Dr. McClay, published from 2002 to 2019. 2019 was the busiest year, with 6. The most frequent topics are Melanoma, Cisplatin and Antineoplastic Combined Chemotherapy Protocols. Dr. McClay has published most often in Gynecol Oncol. Dr. McClay's most frequent co-authors are Sinil Kim, MD, Saeeda Kirmani, MD and Robert O. Dillman, MD, FACP.

Dmand AI links Dr. McClay to 15 clinical trials, 5 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Melanoma, Nevi and Melanomas and Glioblastoma. San Diego Pacific Oncology & Hematology Associates sponsors the most, 4.

CMS Open Payments shows 1,378 general payments to Dr. McClay from 80 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 79% of the total. Bristol-Myers Squibb Company paid the most, $200,592. It also lists 21 research payments totaling $2,239 in 2019.

Dmand AI lists 5 awards for Dr. McClay, most recently Americas Top Doctors for Cancer in 2018.

Dr. McClay graduated from Lewis Katz School of Medicine in 1980.

Dr. McClay is in network with 15 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.